Handelsbanken Fonder Ab Summit Therapeutics Inc. Transaction History
Handelsbanken Fonder Ab
- $25.3 Billion
- Q3 2024
A detailed history of Handelsbanken Fonder Ab transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 88,000 shares of SMMT stock, worth $1.56 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
88,000
Previous 63,900
37.72%
Holding current value
$1.56 Million
Previous $498,000
286.95%
% of portfolio
0.01%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding SMMT
# of Institutions
196Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$434 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$195 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$140 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$96.7 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$61.7 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.58B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...